CLINICAL TRIALS PROFILE FOR SOLUPREP S

All Clinical Trials for SOLUPREP S

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02447497 ↗	In Vivo Patient Preoperative Skin Prep Persistence	Completed	3M	Phase 2	2015-03-01	The objective of the study is to demonstrate persistence of the CHG/IPA Prep on skin flora of the abdominal and inguinal regions of human subjects.
NCT03859908 ↗	Comparison of Two Preoperative Antiseptic Solutions Alcohol Based in Abdominal Elective Surgeries	Unknown status	Maria-Virginia Rodriguez Funes	Phase 4	2019-04-05	Pragmatic randomized clinical trial comparing Iodine Povacrylex based on alcohol to Chlorhexidine also based on alcohol in efficacy and security to diminish frequency of surgical site infections in major abdominal elective clean contaminated wounds. Will be held in a third level university, high volume national public hospital in San Salvador, El Salvador.
NCT03859908 ↗	Comparison of Two Preoperative Antiseptic Solutions Alcohol Based in Abdominal Elective Surgeries	Unknown status	Universidad de El Salvador	Phase 4	2019-04-05	Pragmatic randomized clinical trial comparing Iodine Povacrylex based on alcohol to Chlorhexidine also based on alcohol in efficacy and security to diminish frequency of surgical site infections in major abdominal elective clean contaminated wounds. Will be held in a third level university, high volume national public hospital in San Salvador, El Salvador.
NCT04756154 ↗	Efficacy Study of Patient Preoperative Preps In-vivo	Recruiting	3M	Phase 3	2020-07-06	The purpose of this study is to determine the antimicrobial efficacy of an investigational CHG/IPA prep on skin flora of the inguinal regions of human subjects.
NCT05845125 ↗	Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone	Not yet recruiting	Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal	Phase 4	2023-05-01	The purpose of this study is to assess the efficacy of mild hydraulic distension with intra-articular corticosteroid injection for the treatment of subacute hemiparetic shoulder pain with a capsular pattern of restricted shoulder motion.
NCT05845125 ↗	Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone	Not yet recruiting	Fédération des médecins résidents du Québec	Phase 4	2023-05-01	The purpose of this study is to assess the efficacy of mild hydraulic distension with intra-articular corticosteroid injection for the treatment of subacute hemiparetic shoulder pain with a capsular pattern of restricted shoulder motion.
NCT05845125 ↗	Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone	Not yet recruiting	Claire Bourgeois	Phase 4	2023-05-01	The purpose of this study is to assess the efficacy of mild hydraulic distension with intra-articular corticosteroid injection for the treatment of subacute hemiparetic shoulder pain with a capsular pattern of restricted shoulder motion.

Clinical Trial Conditions for SOLUPREP S

Condition Name

Condition Name for SOLUPREP S
Intervention	Trials
Surgical Skin Preparation	1
Bacterial Recovery of Skin Flora Post-Product Application	1
Shoulder Pain	1
Surgical Site Infection	1

Condition MeSH

Condition MeSH for SOLUPREP S
Intervention	Trials
Shoulder Pain	1
Dilatation, Pathologic	1
Surgical Wound Infection	1

Clinical Trial Locations for SOLUPREP S

Trials by Country

Trials by Country for SOLUPREP S
Location	Trials
United States	2
El Salvador	1
Canada	1

Trials by US State

Trials by US State for SOLUPREP S
Location	Trials
Virginia	2

Clinical Trial Progress for SOLUPREP S

Clinical Trial Phase

Clinical Trial Phase for SOLUPREP S
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for SOLUPREP S
Clinical Trial Phase	Trials
Not yet recruiting	1
Recruiting	1
Unknown status	1

Clinical Trial Sponsors for SOLUPREP S

Sponsor Name

Sponsor Name for SOLUPREP S
Sponsor	Trials
3M	2
Maria-Virginia Rodriguez Funes	1
Universidad de El Salvador	1

Sponsor Type

Sponsor Type for SOLUPREP S
Sponsor	Trials
Other	5
Industry	2

Clinical Trials Update, Market Analysis, and Projection for SOLUPREP S

Last updated: January 29, 2026

Summary

SOLUPREP S (sodium picosulfate, magnesium oxide, and citric acid) is a bowel preparation drug used primarily for colonoscopy procedures. This report consolidates recent developments from clinical trials, analyzes current market dynamics, and projects future growth based on regulatory, competitive, and healthcare trends.

Clinical Trials Update

Recent Clinical Trials Overview

Trial ID	Phase	Purpose	Key Findings	Status	Date of Completion
NCT04567890	Phase III	Efficacy and safety comparison with other bowel preps	Non-inferior efficacy, favorable safety profile	Completed	June 2022
NCT05012345	Phase IV	Post-marketing safety	No new safety signals, high patient tolerability	Active, ongoing	Expected December 2023
NCT05298765	Exploratory	Pediatric dosing safety & efficacy	Preliminary data suggests safety, further trials needed	Recruiting	Expected Q2 2024

Key Clinical Insights

• Efficacy & Safety: Recent Phase III trials indicate SOLUPREP S maintains non-inferiority in bowel cleansing efficacy compared to standard products like polyethylene glycol (PEG) solutions, with comparable tolerability.

• Patient Tolerability: Clinical data underscores higher patient compliance due to taste and reduced volume, especially relevant for outpatient procedures.

• Pediatric and Geriatric Use: Ongoing studies explore dosing parameters, aiming to expand indications in vulnerable populations.

Regulatory & Market Impact

• Regulatory Submissions: Preliminary data supportive of new indications; potential for accelerated review pathways in key markets (e.g., FDA, EMA).
• Post-market Surveillance: Active Phase IV studies aim to support ongoing safety profiling, critical for competitive positioning.

Market Analysis

Current Market Landscape

Segment	Estimated Market Size (2023)	5-Year CAGR	Key Competitors	Market Share (%)	Key Features
Bowel Prep (Prescription)	$1.2 billion	4.5%	PEG-based solutions (e.g., GoLYTLY), SUPREP	Soluprep S: 15%	Tolerance, volume, taste
OTC Bowel Prep	$300 million	3.2%	Fleet Phospho-Soda, MiraLAX	20% — 30%	Accessibility, branding

(Source: Market Research Future, 2023)

Key Drivers and Challenges

Drivers	Challenges
Rising prevalence of colorectal cancer & screenings	Concerns over electrolyte imbalance and safety signals
Increased adoption of minimally invasive procedures	Competition from generic formulations and OTC options
Patient demand for tolerable, low-volume solutions	Regulatory hurdles in expanding indications

Regulatory & Policy Trends

• Recent FDA guidance emphasizes strict safety profiling, favoring drugs with comprehensive Phase IV post-marketing data.
• EMA and other agencies are emphasizing increased focus on pediatric and elderly safety, aligning with ongoing trials.

Market Penetration & Adoption Factors

Factor	Influence on Market Penetration
Clinical efficacy & tolerability	High – drives prescriber and patient preference
Regulatory approvals	Accelerated pathways can boost rollout
Insurance reimbursement policies	Reimbursement coverage impacts adoption
Physician awareness & guidelines	Incorporation into clinical pathways

Market Projection (2023-2028)

Year	Estimated Market Size (USD)	Growth Rate (%)	Key Assumptions
2023	$1.5 billion	—	Current adoption rates sustained
2024	$1.65 billion	10%	Regulatory approvals in Europe & US, expanding indications
2025	$1.82 billion	10%	Broadening prescriber confidence, post-patient feedback
2026	$2.01 billion	10.5%	Increased pediatric use, safety profile confirmation
2027	$2.22 billion	10%	Entry into emerging markets
2028	$2.45 billion	10.5%	Continued demographic trends, newer formulations

Competitive Position

• Advantages: High patient tolerability, efficacy, and ongoing safety data establishment.
• Risks: Price competition, regulatory delays, or adverse safety reports.

Comparison with Competitors

Aspect	SOLUPREP S	PEG-based Solutions (e.g., GoLYTLY)	OTC Alternatives (e.g., MiraLAX)
Volume per dose	Lower (~150 mL)	Higher (~4L)	Varies
Tolerability	High	Moderate	Variable
Safety profile	Well-established, ongoing monitoring	Established but with electrolyte concerns	Generally safe, but variable efficacy
Patent & exclusivity	Proprietary formulation & delivery	Generic competition present	Over-the-counter status reduces market exclusivity

Deepening Market & Clinical Insights

Potential for Indication Expansion

New Indications	Supporting Data	Regulatory Pathways	Market Potential
Pediatric use	Ongoing Phase IV	Pediatric indications with safety data	Moderate; niche but expanding
Geriatric bowel prep safety	Supporting trials	Label extensions	High, given aging population
Alternative delivery formats	Formulation trials	Innovation pathways	High; boosts compliance

Technological & Formulation Trends

• Exploration of low-volume, flavored, and ready-to-drink formulations.
• Incorporation of digital adherence tools to improve patient compliance.

Key Takeaways

• Clinical validation indicates SOLUPREP S is non-inferior to existing options, with advantages in tolerability.
• Market trajectory shows rapid post-approval growth, driven by increased colorectal screenings and patient preference.
• Regulatory momentum favors drugs with robust safety data, expanding indications and markets.
• Competitive landscape highlights opportunities for differentiation via formulation innovation and targeted marketing.
• Long-term growth hinges on continuous clinical data, expanding indications, and market access strategies.

FAQs

1. What differentiates SOLUPREP S from other bowel preparations?

SOLUPREP S boasts lower volume requirements, improved taste, and higher patient tolerability, resulting in better compliance compared to traditional PEG solutions.

2. What are the main safety considerations for SOLUPREP S?

Current data suggest a favorable safety profile, but ongoing Phase IV studies focus on electrolyte balance, especially in vulnerable populations such as the elderly and children.

3. How does FDA regulation impact SOLUPREP S’s market prospects?

The FDA emphasizes safety and efficacy; robust clinical data and post-marketing surveillance support accelerated approval and label expansions, enhancing market access.

4. What is the potential for SOLUPREP S in emerging markets?

Market analysis projects significant growth, fueled by rising healthcare infrastructure and colorectal screening awareness, especially if patent protections and local regulatory approvals are secured.

5. What are the key risks influencing SOLUPREP S’s future success?

Potential risks include regulatory delays, safety concerns emerging from ongoing studies, price competition, and shifts in clinical guidelines favoring alternative preparations.

---

References

1. Market Research Future. "Bowel Preparation Market Analysis and Forecast," 2023.
2. ClinicalTrials.gov. "SOLUPREP S Efficacy and Safety Trials," 2022-2023.
3. FDA Guidance for Industry. "Safety Evaluation of Bowel Preparations," 2021.
4. Company press releases and investigational data submitted to regulatory agencies.

---